| Market Cap | 2.80M | P/E | - | EPS this Y | 99.20% | Ern Qtrly Grth | - |
| Income | -31.54M | Forward P/E | -0.07 | EPS next Y | -6.60% | 50D Avg Chg | -89.00% |
| Sales | 1.92M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -94.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -97.00% |
| Recommedations | 1.00 | Quick Ratio | 1.64 | Shares Outstanding | 1.03M | 52W Low Chg | 14.00% |
| Insider Own | 5.74% | ROA | -53.91% | Shares Float | 860.98K | Beta | 1.17 |
| Inst Own | 6.33% | ROE | - | Shares Shorted/Prior | 153.40K/67.18K | Price | 0.20 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,546,864 | Target Price | 35.00 |
| Oper. Margin | -656.92% | Earnings Date | May 2 | Volume | 2,532,764 | Change | 2.56% |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
| Oppenheimer | Outperform | Apr 16, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 10% Owner 10% Owner | Jun 26 | Sell | 0.57 | 3,683,542 | 2,099,619 | 731,458 | 06/28/23 |
| Caissa Capital Management ltd. | 10% Owner 10% Owner | May 12 | Buy | 2.58 | 4,379 | 11,298 | 1,347,079 | 05/16/23 |
| Caissa Capital Management ltd. | 10% Owner 10% Owner | Apr 10 | Buy | 2.56 | 56,329 | 144,202 | 1,267,700 | 04/11/23 |
| ARMISTICE CAPITAL, LLC | Director Director | Mar 10 | Buy | 0.68 | 226,000 | 153,680 | 47,576,000 | 03/14/22 |
| ARMISTICE CAPITAL, LLC | Director Director | Mar 03 | Buy | 0.69 | 510,000 | 351,900 | 47,350,000 | 03/07/22 |
| ARMISTICE CAPITAL, LLC | Director Director | Feb 24 | Buy | 0.8 | 140,000 | 112,000 | 46,840,000 | 02/28/22 |
| ARMISTICE CAPITAL, LLC | Director Director | Feb 17 | Buy | 0.8 | 288,000 | 230,400 | 46,700,000 | 02/22/22 |
| ARMISTICE CAPITAL, LLC | Director Director | Jan 18 | Buy | 0.87 | 312,000 | 271,440 | 46,412,000 | 01/20/22 |
| ARMISTICE CAPITAL, LLC | Director Director | Jan 12 | Buy | 0.99 | 455,000 | 450,450 | 46,100,000 | 01/14/22 |
| ARMISTICE CAPITAL, LLC | Director Director | Jan 07 | Buy | 0.99 | 645,000 | 638,550 | 45,645,000 | 01/11/22 |
| ARMISTICE CAPITAL, LLC | Director Director | Aug 18 | Buy | 2.77 | 50,000 | 138,500 | 39,300,000 | 08/18/21 |
| - | - - | Jan 12 | Buy | 1.3 | 2,500,000 | 3,250,000 | 32,634,285 | 01/12/21 |
| - | - - | Dec 07 | Buy | 1.22 | 20,000 | 24,400 | 30,134,285 | 12/07/20 |
| - | - - | Nov 25 | Buy | 1.19 | 100,000 | 119,000 | 30,114,285 | 11/25/20 |